Terminated PHASE2 INTERVENTIONAL 4-arm NCT02336425

Efficacy and Safety of QGE031 Compared With Placebo in Patients Aged 18-75 Years With Asthma

A Multi-Center, Randomized, Double-Blind, Placebo- Controlled Study to Investigate the Efficacy and Safety of 52 Weeks Treatment With QGE031 Subcutaneous (s.c). in Asthma Patients Not Adequately Controlled by Medium- or High-dose Inhaled Corticosteroid (ICS) Plus Long Acting β2-agonist (LABA) With or Without Oral Corticosteroid (OCS)

Sponsor: Novartis Pharmaceuticals

Conditions Asthma

Interventions Placebo QGE031

Updated 12 times since 2017 Last updated: Aug 7, 2017 Started: Sep 30, 2015 Primary completion: Mar 31, 2016 Completion: Mar 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This study was terminated due to the efficacy results from an interim analysis (at the end of treatment epoch) of the Phase II study CQGE031B2201 (NCT01716754).

Other terminated trials from Novartis Pharmaceuticals

See all terminations from Novartis Pharmaceuticals

Other Asthma trials with similar outcome

Browse all Asthma trials

A PHASE2 clinical study on Asthma, this trial is terminated or withdrawn. The trial is conducted by Novartis Pharmaceuticals and has accumulated 12 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

12 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE2

▶ Show 7 earlier versions

Nov 2020 — Jan 2021 [monthly]

Terminated PHASE2
Jun 2018 — Nov 2020 [monthly]

Terminated PHASE2
May 2018 — Jun 2018 [monthly]

Terminated PHASE2
Aug 2017 — May 2018 [monthly]

Terminated PHASE2
May 2017 — Aug 2017 [monthly]

Terminated PHASE2

Status: Completed → Terminated
Feb 2017 — May 2017 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Sep 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Balassagyarmat, Hungary , Berlin, Germany , Birmingham, United States , Bojnice, Slovakia , Chuo-ku, Japan , Cottbus, Germany , Edogawa-ku, Japan , Erpent, Belgium , Frankfurt, Germany , Habikino, Japan and 25 more locations